The civic record
Read. Follow. Verify.Proposed Changes to Biosimilar Drug Review Process
Last action · July 21, 2026: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.Sponsors: Ashley Moody and 3 others
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
This bill proposes changes to the to simplify and speed up the federal review process for biological products. These are lower-cost versions of complex, high-cost biological drugs.
The bill aims to reduce the time and regulatory burden for bringing medications to market, which could impact the availability and pricing of specialized treatments for patients relying on biological therapies.
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
Pharmaceutical manufacturers
Companies developing biosimilar products will be subject to the updated review procedures established by this amendment.
Patients using biological therapies
Patients may experience changes in the availability or cost of biological treatments depending on how the streamlined review process affects market entry for biosimilars.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
What is a biosimilar biological product?
What is the current status of this bill?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently in committee. The next step in the legislative lifecycle is Floor Vote.
Procedural history
2 actions- Jul 21, 2026SenateCommitteeRead twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Jul 21, 2026SenateIntroducedIntroduced in Senate
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Focus on Regulatory Efficiency
The bill signals a legislative intent to prioritize the reduction of regulatory hurdles for biosimilar market entry.
Connected Entities
Sources
www.congress.gov
Analysis Score
0–100- Significance65How much this matters to a regular citizen
- Controversy40Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz20Current news / social attention level
Publisher tools